Sun Pharma reported a 20% decline in Q1FY26 net profit to ₹2,279 crore, compared to ₹2,835 crore last year. However, profit increased 6% from the previous quarter, while consolidated revenue rose 9% to ₹13,851 crore from ₹12,653 crore in Q1FY25.
Recent Posts
- Michael Saylor Says Strategy’s Current Capital Structure ‘Bulletproof’ Compared To 2022 Crypto Winter, Asserts Company Can Weather 80% Bitcoin Crash
- WeRide Records Another Strong Quarter in Q2 2025: Revenue Hits US$17.8 Million, Robotaxi Revenue Increases 836.7% YoY to US$6.4 Million
- Defence stock in focus after receiving ₹6 Cr order from Indian Navy
- Infra stock jumps after receiving ₹76 Cr civil contract order in Maharashtra
- Telecom stock in focus after ICICI Securities indicates 30% downside amid poor Q1 performance